Your browser doesn't support javascript.
loading
Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study.
Mao, Xianhua; Cheung, Ka Shing; Tan, Jing-Tong; Mak, Lung-Yi; Lee, Chi-Ho; Chiang, Chi-Leung; Cheng, Ho Ming; Hui, Rex Wan-Hin; Yuen, Man Fung; Leung, Wai Keung; Seto, Wai-Kay.
  • Mao X; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
  • Cheung KS; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong cks634@hku.hk wkseto@hku.hk.
  • Tan JT; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
  • Mak LY; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
  • Lee CH; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
  • Chiang CL; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
  • Cheng HM; Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong Kong.
  • Hui RW; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
  • Yuen MF; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
  • Leung WK; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
  • Seto WK; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Gut ; 2024 Apr 03.
Article en En | MEDLINE | ID: mdl-38569845
ABSTRACT

OBJECTIVE:

Whether varying degrees of glycaemic control impact colonic neoplasm risk in patients with diabetes mellitus (DM) remains uncertain.

DESIGN:

Patients with newly diagnosed DM were retrieved from 2005 to 2013. Optimal glycaemic control at baseline was defined as mean haemoglobin A1c (HbA1c)<7%. Outcomes of interest included colorectal cancer (CRC) and colonic adenoma development. We used propensity score (PS) matching with competing risk models to estimate subdistribution HRs (SHRs). We further analysed the combined effect of baseline and postbaseline glycaemic control based on time-weighted mean HbA1c during follow-up.

RESULTS:

Of 88 468 PS-matched patients with DM (mean (SD) age 61.5 (±11.7) years; male 47 127 (53.3%)), 1229 (1.4%) patients developed CRC during a median follow-up of 7.2 (IQR 5.5-9.4) years. Optimal glycaemic control was associated with lower CRC risk (SHR 0.72; 95% CI 0.65 to 0.81). The beneficial effect was limited to left-sided colon (SHR 0.71; 95% CI 0.59 to 0.85) and rectum (SHR 0.71; 95% CI 0.57 to 0.89), but not right-sided colon (SHR 0.86; 95% CI 0.67 to 1.10). Setting suboptimal glycaemic control at baseline/postbaseline as a reference, a decreased CRC risk was found in optimal control at postbaseline (SHR 0.79), baseline (SHR 0.71) and both time periods (SHR 0.61). Similar associations were demonstrated using glycaemic control as a time-varying covariate (HR 0.75). A stepwise greater risk of CRC was found (Ptrend<0.001) with increasing HbA1c (SHRs 1.34, 1.30, 1.44, 1.58 for HbA1c 7.0% to <7.5%, 7.5% to <8.0%, 8.0% to <8.5% and ≥8.5%, respectively). Optimal glycaemic control was associated with a lower risk of any, non-advanced and advanced colonic adenoma (SHRs 0.73-0.87).

CONCLUSION:

Glycaemic control in patients with DM was independently associated with the risk of colonic adenoma and CRC development with a biological gradient.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article